Navigation Links
Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
Date:11/21/2007

re treatable. For additional information, please visit http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of brostallicin include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with brostallicin in particular including, without limitation, the potential failure of brostallicin to prove safe and effective for treatment of solid tumors, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling brostallicin, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by Italian law, CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200

Susan Callahan

T: 206.272.4472

F: 206.272.4434

E: media@ctiseattle.com

http://www.cticseattle.com/media.htm

Investors Contact:

Leah Grant

T: 206.282.7100

F: 206.272.4434

E: invest@ctiseattle.com

http://www.cticseattle.com/investors.htm


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Phase III Trial Finds Pharmaxis Bronchitol Effective
9. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
10. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 ­ RedBrick Health , ... change technology, today announces that EmblemHealth , the ... wellness company, is now providing the RedBrick Compass health ... program, to all of its members. EmblemHealth is among ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 The Microcompetition with ... major disease. One of these latent viruses is the Epstein ... arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease ... a study found that RA patients have high concentrations of ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that ... leading Russian pharmaceutical company, to develop and commercialize nemonoxacin ... , Turkey and other ... novel antibiotic for the treatment of bacterial infections including ...
(Date:1/14/2014)... Calif. , Jan. 14, 2014 As pet owners drew ... doubt many of them wrote: "Take better care of my furry ... even designer clothes and top-brand carrying cases to take the little ... parents might also feel compelled to buy some pricey toys at ...
Breaking Biology Technology:EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
... done and now they,ve done it. What,s more, they did ... U.S. Department of Energy (DOE),s Lawrence Berkeley National Laboratory (Berkeley ... the first experimental demonstration of GRIN for gradient index ... a wide range of exotic optics, including superfast computers based ...
... 2011 Amgen (Nasdaq: AMGN ) and ... into a definitive acquisition agreement under which Amgen has ... venture-funded,  biotechnology company headquartered in Woburn, Mass. BioVex is ... Phase 3 clinical development, that may represent a new ...
... (Nasdaq: CEPH ) will hold a public memorial service ... and CEO on February 1, 2011, at 6:00 p.m. at The ... Dr. Baldino founded Cephalon in 1987 and led the ... ten biotechnology companies in the world. He was a recognized pioneer ...
Cached Biology Technology:GRIN plasmonics 2GRIN plasmonics 3GRIN plasmonics 4Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass 2Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass 3Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass 4Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass 5Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass 6Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass 7Cephalon to Hold Public Memorial Service to Celebrate the Life of Company Founder, Frank Baldino, Jr., Ph.D. 2
(Date:4/23/2014)... 2014) A team of researchers in ... into the brains of nonhuman primates and assessed ... months found that the hNSCs had differentiated into ... tumors. , The study will be published in ... but is currently freely available on-line as an ...
(Date:4/23/2014)... evidence of an interaction between prenatal smoking and ... children, especially in girls. , "The interesting issue ... smoking will have behavioral problems. Some might, ... Professor at Sam Houston State University, College of ... "One possible explanation for this is that ...
(Date:4/23/2014)... Climate fiction, or simply cli-fi, is a newly coined term ... global warming. New research from University of Copenhagen shows how ... to simulate the potential consequences of climate change and imagine ... than scientific data on changes in the atmosphere; it is ... by the books we read and the films we see. ...
Breaking Biology News(10 mins):Study finds long-term survival of human neural stem cells transplanted into primate brain 2Genetics risk, prenatal smoking may predict behavioral problems 2Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3
... One of the challenges of gene therapy - a ... (DNA or RNA) - is to assure that this material ... a substantial amount along the way and without producing any ... the use of different types of vectors, molecules capable of ...
... shellfish safer to eat has been pioneered by scientists at ... Institute for Agri-Food and Land Use, not only ensures shellfish ... but is likely to revolutionise the global fishing industry. While ... takes up to two days, the new test slashes the ...
... Aware, Inc. (Nasdaq: AWRE ), a leading ... industries, today announced that on January 5, 2011 its Board ... S. Stafford, III to the Aware Board of Directors.   ... Director and will serve on the Board,s Nominating and Corporate ...
Cached Biology News:Nanodisk gene therapy 2Shellfish safer to eat thanks to breakthrough by Queen's scientists 2Aware Announces Appointment of New Directors 2Aware Announces Appointment of New Directors 3